195 related articles for article (PubMed ID: 18668443)
21. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Takano M; Hasegawa R; Fukuda T; Yumoto R; Nagai J; Murakami T
Eur J Pharmacol; 1998 Oct; 358(3):289-94. PubMed ID: 9822896
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
23. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
24. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
Zhang S; Morris ME
Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
[TBL] [Abstract][Full Text] [Related]
25. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
Zhang H; Yao M; Morrison RA; Chong S
Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
[TBL] [Abstract][Full Text] [Related]
26. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
Störmer E; von Moltke LL; Perloff MD; Greenblatt DJ
Pharm Res; 2002 Jul; 19(7):1038-45. PubMed ID: 12180537
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
28. Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.
Crowe A; Wong P
Toxicol Appl Pharmacol; 2003 Nov; 193(1):127-37. PubMed ID: 14613723
[TBL] [Abstract][Full Text] [Related]
29. Chronic administration of verapamil, ketoconazole and carbamazepine: impact on immunological parameters.
Bonhomme-Faivre L; Forestier F; Auchère D; Soursac M; Orbach-Arbouys S; Farinotti R
Int J Pharm; 2002 May; 238(1-2):133-7. PubMed ID: 11996817
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM
Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403
[TBL] [Abstract][Full Text] [Related]
32. Grapefruit juice activates P-glycoprotein-mediated drug transport.
Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
[TBL] [Abstract][Full Text] [Related]
33. Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells.
Utoguchi N; Chandorkar GA; Avery M; Audus KL
Reprod Toxicol; 2000; 14(3):217-24. PubMed ID: 10838122
[TBL] [Abstract][Full Text] [Related]
34. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
35. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Perloff MD; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 2002 Nov; 42(11):1269-74. PubMed ID: 12412827
[TBL] [Abstract][Full Text] [Related]
36. The anthelminthic agent albendazole does not interact with p-glycoprotein.
Merino G; Alvarez AI; Prieto JG; Kim RB
Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
[TBL] [Abstract][Full Text] [Related]
37. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
38. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
39. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
40. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
Bhardwaj RK; Glaeser H; Becquemont L; Klotz U; Gupta SK; Fromm MF
J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
